CRMD
CorMedix Inc.
Key Financials
Operating Income
$150.1M
↑ 771.6%
Net Income
$163.1M
↑ 1009.4%
Revenue
$127.4M
N/A
Total Assets
$826.1M
↑ 595.1%
Gross Profit
$275.7M
↑ 584.6%
EPS (Diluted)
$2.04
↑ 780.0%
Cash & Equivalents
$144.8M
↑ 256.3%
Shareholders' Equity
$405.3M
↑ 378.8%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 6/12/2026 | View on SEC |
| SCHEDULE 13G/A | 6/12/2026 | View on SEC |
| 8-K | 6/8/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 10-Q | 5/14/2026 | View on SEC |
| 8-K | 5/14/2026 | View on SEC |
| ARS | 4/29/2026 | View on SEC |
| DEFA14A | 4/29/2026 | View on SEC |
| DEF 14A | 4/29/2026 | View on SEC |
| 8-K | 4/27/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | CRMD |
| Company Name | CorMedix Inc. |
| CIK | 1410098 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 908-517-9500 |